Nuwellis (NASDAQ: NUWE) — Company Overview, News & Financial Data
Nuwellis specializes in advanced fluid management solutions for critical care, improving patient outcomes in healthcare.
Nuwellis
Nuwellis (NASDAQ:NUWE) specializes in advanced fluid management solutions aimed at tackling critical care challenges within the healthcare sector. Its innovative technology platform, primarily the Aquadex SmartFlow system, is designed to remove excess fluid from patients suffering from conditions like heart failure and other related issues, thereby improving their overall condition and optimizing patient care. The focus of Nuwellis extends into research and development with a strong commitment towards enhancing and innovating its product offerings, ensuring they meet the evolving needs of healthcare providers and patients alike. Projects often revolve around clinical studies to further validate the efficacy and safety of their systems, aspiring to expand their application in medical treatments globally. The primary objective for Nuwellis is to improve patient outcomes by delivering precise, personalized fluid management solutions, affirming their dedication to improving the quality of life for patients with complex medical conditions.
Snapshot
Operations
Products and/or services of Nuwellis
- Aquadex FlexFlow system, a comprehensive diuretic therapy management for fluid overloaded patients, prioritizing heart failure treatment.
- Aquadex SmartFlow Console, a next-generation console for precise fluid management, enhancing patient care in various fluid overload conditions.
- Ultrafiltration Catheters, designed for efficient fluid removal, compatible with Aquadex systems, improving patient outcomes.
- Clinical research initiatives focused on expanding the application of ultrafiltration therapy across different patient populations, informing best practices.
- Educational programs for healthcare professionals, offering training and resources on ultrafiltration therapy, aimed at improving patient care.
- Customer support services, providing technical assistance and guidance for their product line to ensure optimal usage and patient safety.
Nuwellis executive team
- Michael Kendrick McCormickPresident, CEO & Director
- Neil P. AyotteSenior VP, General Counsel, Secretary & Chief Compliance Officer
- Carisa SchultzCFO, Principal Financial Officer & Principal Accounting Officer
- Kim AndersonVice President, Research & Development, Quality and Operations
- David LernerChief Technology Officer
- Leah McMullenDirector of Communications
- Paul WottaCorporate Controller
Key financials
Reported results for Nuwellis, in USD.
- Market cap
- 2.1M
- Revenue (TTM)
- 9M
- P/E ratio
- 0.0
- EPS (diluted, TTM)
- 3923.3
- Dividend yield
- —
- Profit margin
- -125.6%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 8.3M | -11.1M | -17.5M | |
| 8.7M | -11M | -11.2M | |
| 8.9M | -17.6M | -20.2M | |
| 8.5M | -17.2M | -14.5M |